Manu Kaushik, MD
Interventional Cardiology · Milwaukee, WINPI 1740489202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,286 of the $12,078 with a category attached, or 76.9%. It is spread thinly across 32 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 256 payments — averaging $47.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Edwards Lifesciences$2K
- Boston Scientific$2K
- Medtronic$1K
- Abiomed$1K
- Intuitive Surgical$1K
- plus $3K from 26 others
What the payments were for
- Travel & lodging$2,71122%
- Food & beverage$9,28677%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 35 | $2,686 |
| Edwards Lifesciences | 20 | $1,593 |
| Boston Scientific | 29 | $1,556 |
| Medtronic(2 entities) | 40 | $1,236 |
| Abiomed | 15 | $1,162 |
| Intuitive Surgical | 4 | $1,008 |
| Shockwave Medical, Inc | 5 | $547 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $276 |
| W. L. Gore & Associates, Inc. | 2 | $273 |
| Johnson & Johnson | 15 | $247 |
| Penumbra, Inc. | 5 | $212 |
| Pfizer | 11 | $190 |
| E.r. Squibb & Sons, L.L.C. | 9 | $119 |
| Astellas Pharma US Inc | 6 | $116 |
| Amgen | 6 | $101 |
| Biosense Webster, Inc. | 1 | $101 |
| Cardiovascular Systems Inc. | 5 | $100 |
| AstraZeneca | 7 | $100 |
| Novartis | 4 | $94 |
| Cardiva Medical, Inc. | 3 | $72 |
| Philips North America LLC | 2 | $52 |
| Amarin Pharma, Inc. | 2 | $45 |
| Teleflex LLC | 2 | $38 |
| Heartflow, Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Getinge USA Sales, LLC | 1 | $20 |
| Cvrx, Inc. | 2 | $19 |
| Bayer | 1 | $18 |
| Atricure, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Cordis US CORP. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$970
- Mitra Clip system$899
- TRICLIP$814
- Impella$510
- WATCHMAN FLX$434
- SAPIEN 3 Ultra RESILIA$387
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$319
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$295
- PASCAL$281
- GORE CARDIOFORM Septal Occluder$273
- COREVALVE EVOLUT R$250
- EVOQUE$145
- Optis Coronary Imaging System$135
- VenaSeal$129
- ROTABLATOR$115
- GENERAL ATHERECTOMY$109
- Indigo System$104
- Carto 3$101
- MitraClip System$100
How this compares
$12,078 in reported general payments places this provider in the 70th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $123,805 |
| EntrestoSacubitril/Valsartan | 56 | $61,220 |
| Repatha SureclickEvolocumab | 18 | $20,530 |
| FarxigaDapagliflozin Propanediol | 13 | $14,969 |
| Repatha SyringeEvolocumab | 14 | $8,824 |
| CorlanorIvabradine Hcl | 12 | $8,082 |
| Rosuvastatin Calcium | 196 | $2,732 |
| Ezetimibe | 79 | $2,143 |
| Amiodarone Hcl | 27 | $1,742 |
| Atorvastatin Calcium | 134 | $1,741 |
| Metoprolol Succinate | 105 | $980 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $965 |
| Carvedilol | 107 | $953 |
| Losartan Potassium | 110 | $942 |
| ClopidogrelClopidogrel Bisulfate | 74 | $764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $190 | $123,805136 claims |
| NovartisEntresto | $94 | $61,22056 claims |
| AstraZenecaFarxiga | $100 | $14,96913 claims |
| AmgenCorlanor | $101 | $8,08212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Milwaukee
- Michael SalingerMilwaukee$216K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Iyad AzzamMilwaukee$60K
- Montoya TaylorMilwaukee$48K
- Mina IskanderMilwaukee$41K
- Anna LarosaMilwaukee$38K
- Louie KostopoulosMilwaukee$26K
- Daniel JohnsrudMilwaukee$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.